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Summary
Background Although the burden of disease in sub-Saharan Africa continues to be dominated by infectious diseases, 
countries in this region are undergoing a demographic transition leading to increasing prevalence of non-
communicable diseases (NCDs). To inform health system responses to these changing patterns of disease, we aimed 
to assess changes in the burden of NCDs in sub-Saharan Africa from 1990 to 2017.
Methods We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to analyse 
the burden of NCDs in sub-Saharan Africa in terms of disability-adjusted life-years (DALYs)—with crude counts as 
well as all-age and age-standardised rates per 100 000 population—with 95% uncertainty intervals (UIs). We examined 
changes in burden between 1990 and 2017, and differences across age, sex, and regions. We also compared the 
observed NCD burden across countries with the expected values based on a country’s Socio-demographic Index.
Findings All-age total DALYs due to NCDs increased by 67·0% between 1990 (90·6 million [95% UI 81·0–101·9]) and 
2017 (151·3 million [133·4–171·8]), reflecting an increase in the proportion of total DALYs attributable to NCDs (from 
18·6% [95% UI 17·1–20·4] to 29·8% [27·6–32·0] of the total burden). Although most of this increase can be explained 
by population growth and ageing, the age-standardised DALY rate (per 100 000 population) due to NCDs in 2017 
(21 757·7 DALYs [95% UI 19 377·1–24 380·7]) was almost equivalent to that of communicable, maternal, neonatal, 
and nutritional diseases (26 491·6 DALYs [25 165·2–28 129·8]). Cardiovascular diseases were the second leading cause 
of NCD burden in 2017, resulting in 22·9 million (21·5–24·3) DALYs (15·1% of the total NCD burden), after the 
group of disorders categorised as other NCDs (28·8 million [25·1–33·0] DALYs, 19·1%). These categories were 
followed by neoplasms, mental disorders, and digestive diseases. Although crude DALY rates for all NCDs have 
decreased slightly across sub-Saharan Africa, age-standardised rates are on the rise in some countries (particularly 
those in southern sub-Saharan Africa) and for some NCDs (such as diabetes and some cancers, including breast and 
prostate cancer).
Interpretation NCDs in sub-Saharan Africa are posing an increasing challenge for health systems, which have to date 
largely focused on tackling infectious diseases and maternal, neonatal, and child deaths. To effectively address these 
changing needs, countries in sub-Saharan Africa require detailed epidemiological data on NCDs.
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Introduction
In sub-Saharan Africa, communicable diseases such as 
malaria, tuberculosis, and HIV have long been among 
the most prominent contributors to disease burden.1 
However, like most low-income and middle-income 
countries across the globe, countries in sub-Saharan 
Africa are undergoing a rapid epidemiological transition 
characterised by a shift from disease-burden profiles 
dominated by communicable diseases and childhood 
illnesses to profiles featuring an increasing pre-
dominance of chronic, non-communicable diseases 
(NCDs). Our understanding of the epidemiology of 
NCDs in sub-Saharan Africa is limited by the lack 
of established vital statistics systems and reliable 
population-level data for most countries in the region.2 
Nonetheless, research indicates growing burdens of 
diabetes,3,4 chronic respiratory diseases,5 chronic kidney 
disease,6 cardio vascular diseases,7,8 cancers,9 and mental 
and substance use disorders10,11 in numerous countries 
in sub-Saharan Africa. Furthermore, sub-Saharan Africa 
is expected to see one of the largest increases in mortality 
due to NCDs globally.2 NCD risk factor surveillance in 
sub-Saharan Africa over the past decade indicates that 
most adults are exposed to at least one risk factor for 
NCDs, including tobacco consumption, harmful alcohol 
use, unhealthy diet, physical inactivity, obesity, or high 
blood pressure.12
Global recognition of the growing challenges posed by 
NCDs is reflected in the UN Sustainable Development 
Goals, which include a target to reduce premature deaths 
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due to major NCDs by 30% by 2030 and promote mental 
health and general wellbeing.13,14 The WHO Global NCD 
Action Plan 2013–2020 also outlines global targets to 
reduce mortality due to major NCDs.15 To achieve these 
targets, health systems will need to be equipped to 
address the changing patterns of disease burden; 
however, according to the NCD policy indicators outlined 
in the action plan, countries across sub-Saharan Africa 
do not have the appropriate measures in place to aid 
with reaching the targets. In many sub-Saharan African 
countries, health systems remain fragile, fragmented, 
under-resourced, and limited in terms of infrastructure 
and capacity to address the increasing burden of 
NCDs.16,17 As NCDs increase in prevalence, existing 
barriers to treatment will become more apparent.16,18 
Determining which NCDs should be prioritised, both 
now and in the future, is necessary for local health 
service planning and ongoing global health efforts in 
sub-Saharan Africa.19
In this study, we used estimates from the Global Burden 
of Diseases, Injuries, and Risk Factors Study (GBD) 2017—
which uses methods that allow for the estimation of 
burden in countries or regions with scarce data—to 
provide a comprehensive and in-depth examination of the 
burden of NCDs in sub-Saharan Africa and to analyse the 
change in NCD burden from 1990 to 2017 at the regional 
and country levels. We aimed to investigate the role of 
NCDs in the epidemiological transition in sub-Saharan 
Africa; the burden of NCDs by cause, and how this 
changed between 1990 and 2017; the burden of NCDs by 
region, age, and sex; and the variations in NCD burden 
across countries according to the social, economic, and 
demo graphic variation between countries, as measured 
by the Socio-demographic Index (SDI).
Methods
Overview
All GBD 2017 estimates were generated and are reported 
here in accordance with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (appendix p 1). 
The methods used by GBD 2017 are described in detail 
elsewhere.20 The estimation process for NCDs in GBD 
2017 is briefly summarised below.
The GBD 2017 cause list was made up of a four-level 
hierarchy. Causes reported within each level are 
mutually exclusive and collectively exhaustive (appendix 
p 7). Level 2 NCDs featured in GBD 2017 were 
cardiovascular diseases; neoplasms (cancers); chronic 
respiratory dis eases; diabetes, urogenital, blood, and 
endocrine dis orders; neurological disorders; cirrhosis; 
digestive diseases; mental disorders; substance use 
disorders; musculo skeletal disorders; and other non-
commun icable diseases (including congenital anom-
alies, sense organ diseases, skin and subcutaneous 
diseases, and oral disorders).
GBD 2017 uses the disability-adjusted life-year (DALY) 
to measure disease burden at the population level. 
DALYs are calculated by summing years of life lost (YLLs) 
due to premature mortality and years of life lived with 
disability (YLDs), thereby incorporating both fatal and 
non-fatal burden.20 All estimates generated in GBD 2017 
were accompanied by 95% uncertainty intervals (UIs). 
DALYs, YLDs, and YLLs were estimated for each NCD by 
sex, age (20 age groups spanning the entire lifespan), year 
Research in context
Evidence before this study
We searched PubMed (Dec 12, 2018) using the terms “NCD”, 
“noncommunicable diseases”, “burden”, “prevalence”, 
“mortality”, “morbidity”, “Africa”, and “sub-Saharan” for articles 
published in English. The burden of communicable, maternal, 
neonatal, and nutritional (CMNN) diseases continues to be very 
high in sub-Saharan Africa relative to other regions. Data on the 
prevalence of certain non-communicable diseases (NCDs) and 
their risk factors are increasingly being generated for some 
countries in sub-Saharan Africa; however, to our knowledge, 
a comprehensive assessment of all major NCDs across all 
countries in sub-Saharan Africa including estimates over a long 
period has not previously been published. This information is 
needed to allow informed health-system and policy 
development across sub-Saharan African regions and countries. 
The burden of disease in sub-Saharan Africa has been estimated 
by the Global Burden of Disease Study (GBD), but trends in NCDs 
across this super-region have not been comprehensively assessed 
and analysed to our knowledge. GBD 2017 became available in 
2018 and is the latest in the series of GBD efforts since 1990.
Added value of this study
This study provides a comprehensive overview of the burden 
of NCDs in sub-Saharan Africa from 1990 to 2017, based on GBD 
2017 data. GBD 2017 is the most recent peer-reviewed assessment 
of disease burden by age group, sex, cause, and location. 
The findings of this study will help countries to identify priority 
areas for interventions and will also serve as a baseline for 
analysing the effectiveness of programmes and policies over time.
Implications of all the available evidence
The findings of this study describe the burden of broad disease 
groups and specific diseases across sub-Saharan Africa. 
Although the burden due to CMNN diseases continues to 
dominate in sub-Saharan Africa as a whole, many NCDs are on 
the rise, especially as populations increase in number and age. 
Accordingly, the enhancement of interventions to control NCDs 
must happen in every country, in parallel with measures to 
address the burden of CMNN diseases. Current uncertainty 
around estimates of disease burden indicates the need for 
improved data in sub-Saharan Africa, and we call for reinforced 
efforts to strengthen health information systems.
See Online for appendix
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(six timepoints from 1990 to 2017 are presented), and 
location (195 countries and territories further aggregated 
into 21 regions and seven super-regions). Age-
standardised rates were estimated on the basis of the 
GBD world population age standard. Sub-Saharan Africa 
is a super-region made up of 46 countries among four 
GBD regions: western sub-Saharan Africa, eastern sub-
Saharan Africa, central sub-Saharan Africa, and southern 
sub-Saharan Africa (appendix p 18).
YLLs because of premature mortality
For direct causes of death, YLLs were calculated by 
multiplying the number of deaths for a given age group, 
sex, year, and location by the reference life expectancy. 
GBD 2017 estimated cause-specific deaths using data 
from vital registries, verbal autopsies, and other mortality 
surveillance databases. The International Classification 
of Diseases (ICD) coding system (ICD-9 and ICD-10) was 
used to assign each death to its direct physical cause. 
Deaths allocated to ambiguous or incorrect cause codes 
were redistributed with redistribution algorithms 
developed specifically for GBD purposes. For most GBD 
causes, death estimates were analysed with the Cause of 
Death Ensemble Modelling (CODEm) tool. Normative 
lifetables were calculated using the lowest death rates for 
each age group in locations with populations greater 
than 5 million. The reference life expectancy estimated 
was 86·6 years at birth and 23·8 years at 65 years. The 
cause of death data and model specifications are further 
detailed elsewhere.1
YLDs
For each cause, YLDs were calculated by multiplying 
estimates of prevalence for each age group, sex, year, 
and location by a corresponding disability weight. 
The epidemiological modelling, disability weights and 
comorbidity adjustments are described briefly here 
and in detail elsewhere.21
Systematic literature reviews were done to capture 
epidemiological data from health surveys, surveillance 
systems, disease registries, and hospital and claims 
databases. For most causes, epidemiological data were 
modelled with use of DisMod-MR 2.1, a Bayesian meta-
regression tool designed specifically for GBD purposes. 
DisMod-MR 2.1 was used to estimate the prevalence of 
diseases, including for countries or regions that were 
lacking data, as well as to provide an assessment of 
internal consistency and UIs. Details of data input 
sources are available online.
Following the estimation of disease prevalence, 
additional steps were taken to estimate prevalent cases of 
each cause by severity. For some causes (eg, chronic 
obstructive pulmonary disease), severity was modelled via 
DisMod using data gathered in different locations around 
the world. Other causes use severity proportions from 
meta-analyses. For the remaining causes, individual-level 
survey data from the Medical Expenditure Panel Survey, 
the National Epidemiologic Survey on Alcohol and Related 
Conditions, and the 1997 Australian National Survey of 
Mental Health and Wellbeing were used to estimate the 
proportion of cases with each cause that were within each 
level of severity.22 Each level of severity for each cause has 
an associated health state with a disability weight. These 
disability weights were derived from responses of more 
than 60 000 participants in an online internet survey and 
population surveys in Bangladesh, Indonesia, Peru, 
Tanzania, the USA, Hungary, Italy, Sweden, and the 
Netherlands. In the surveys, participants were presented 
with pairs of non-clinical descriptions of sequelae and 
asked which was the healthier of the two. Responses were 
converted into disability weights, anchored on a scale from 
0 (perfect health) to 1 (death), using questions comparing 
the benefits of life-saving and disease-prevention 
programmes.23
The burden associated with each non-fatal sequela was 
first estimated independently to other sequelae; however, 
individuals often live with multiple sequelae at a time. 
For the GBD 2017 data input 
sources tool see http://ghdx.
healthdata.org/gbd-2017/data-
input-sources
Figure 1: Trends of cause groups 1, 2, and 3, 1990–2017
(A) Absolute DALYs (millions). (B) All-age DALY rates (per 100 000 population). 
(C) Age-standardised DALY rates (per 100 000 population). Shaded regions 
are 95% uncertainty intervals. DALY=disability-adjusted life-year. 
Group 1=communicable, maternal, neonatal, and nutritional disorders. 
Group 2=non-communicable diseases. Group 3=injuries. 
Group 1 Group 2 Group 3
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Age-standardised DALYs per 100 000 population All-age DALYs per 100 000 population All-age total DALYs (thousands)
1990 2017 Percentage 
change, 
1990–2017
1990 2017 Percentage 
change, 
1990–2017
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Age-standardised DALYs per 100 000 population All-age DALYs per 100 000 population All-age total DALYs (thousands)
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change, 
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A microsimulation method was used to create hypothetical 
populations (by age, sex, year, and location) and adjust for 
the independent probability of experiencing more than 
one disease sequela. The difference in disability weights 
for individuals experiencing one sequela and the 
multiplicatively combined disability weight in those 
experiencing two or more sequelae was the comorbidity 
correction. The average comorbidity correction for each 
sequela was applied to the corresponding location-specific, 
age-specific, sex-specific, and year-specific YLD.
SDI
The SDI is a composite measure of development made 
up of the geometric mean of three common indicators: 
Age-standardised DALYs per 100 000 population All-age DALYs per 100 000 population All-age total DALYs (thousands)
1990 2017 Percentage 
change, 
1990–2017
1990 2017 Percentage 
change, 
1990–2017
1990 2017 Percentage 
change, 
1990–2017
(Continued from previous page)




















































































































































Data in parentheses are 95% uncertainty intervals. DALY=disability-adjusted life-year.
Table: Age-standardised and all-age DALY rates and total DALYs in 1990 and 2017, and percentage change from 1990 to 2017
Figure 2: Burden of non-communicable diseases globally and by sub-Saharan African region, 2017
Data are age-standardised DALYs per 100 000 population. DALY=disability-adjusted life-year.
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income per capita, average years of schooling among 
people aged 15 years or older, and the total fertility 
rate.20 The SDI metric was scaled to values ranging 
from 0 to 1, where 0 indicates the lowest income, lowest 
level of schooling, and highest fertility rate. Spline 
regressions were used to estimate the relationships 
between burden measures (DALYs, YLLs, and YLDs) 
and SDI and to estimate the expected values at each 
level of SDI.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between 1990 and 2017, the total number of DALYs due to 
NCDs for all ages increased rapidly in sub-Saharan Africa, 
from around 90·6 million (95% UI 81·0–101·9) to 
151·3 million (133·4–171·8), representing a 67·0% 
increase (figure 1, table). Of the total burden of disease 
across sub-Saharan Africa from 1990 (486·0 million 
[469·6–503·3] DALYs) to 2017 (507·6 million [477·7–543·7] 
DALYs), the proportion of NCDs increased from 18·6% 
(95% UI 17·1–20·4) to 29·8% (27·6–32·0). Meanwhile, 
communicable, maternal, neonatal, and nutritional 
(CMNN) diseases declined, particularly from 2005 
onwards, despite a notable increase in the burden of 
HIV/AIDS between 1995 and 2005 (figure 1). The growth 
in population size was the key driver of NCD burden over 
this period and, accounting for changes in population 
age-structure, the age-standardised DALY rate due to 
NCDs (21 757·7 DALYs per 100 000 population [95% UI 
19 377·1–24 380·7]) is now almost equivalent to that for 
CMNN diseases (26 491·6 DALYs per 100 000 population 
[25 165·2–28 129·8]; figure 1).
Apart from the group categorised as other NCDs, 
which includes congenital anomalies and accounted for 
around 28·8 million (25·1–33·0) DALYs (19·1% of the 
total NCD burden), cardiovascular diseases were the 
leading level 2 causes of NCD burden across sub-Saharan 
Africa in 2017, contributing more than 22·9 million 
(95% UI 21·5–24·3) DALYs, or 15·1% of the total NCD 
burden (table). The next most prominent level 2 causes 
were neoplasms (contributing 16·9 million [15·7–18·3] 
DALYs, 11·2%) and mental disorders (13·6 million 
[9·9–17·7] DALYs, 9·0%). Although uncertainties 
around these estimates were large, total DALYs due to 
mental disorders increased by 113·9% between 1990 and 
2017, while DALYs associated with neoplasms increased 
by 79·5%. Within neoplasms, cervical and breast cancers 
were the leading causes of disease burden in 2017, 
followed by liver cancer (table). For most types of 
neoplasm, all-age and age-standardised DALY rates per 
100 000 population declined across sub-Saharan Africa 
between 1990 and 2017; however, rates of several cancers 
(including pancreatic, prostate, and breast) increased 
(table). 
Diabetes also contributes a large disease burden. Total 
DALYs due to diabetes increased by 126·4% between 1990 
and 2017—the tenth largest change observed across all 
level 3 causes of NCD burden. Diabetes in sub-Saharan 
Africa has not only increased in terms of total DALYs, but 
also in terms of crude and age-standardised DALY rates, 
as well as YLL and YLD rates (appendix p 19).
Although the total number of DALYs due to NCDs 
has been increasing rapidly in sub-Saharan Africa, 
crude DALY rates due to NCDs overall declined by 
20·0% during the 1990–2017 period, from 18 442·4 DALYs 
(16 489·4–20 742·2) to 14 746·3 DALYs (12 998·6–16 739·2) 
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per 100 000 population. The increase in total DALYs due 
to NCDs can be largely explained by the population 
growth over this period and, to a lesser extent, by 
population ageing (appendix p 27). Only in southern 
sub-Saharan Africa were changes substantially explained 
by an ageing population. Notably, several countries in 
this region, including Zimbabwe and Lesotho, have seen 
rapid increases in NCD burden in terms of both absolute 
DALYs and DALY rates, in contrast to other countries in 
sub-Saharan Africa, where age-standardised DALY rates 
have decreased (appendix p 28).
Compared with global estimates, age-standardised 
DALY rates by sex in each sub-Saharan African region 
show that sub-Saharan Africa had a high burden of NCDs 
overall in 2017 (figure 2). Males and females in all regions 
of sub-Saharan Africa had higher DALY rates for 
NCDs collectively compared with the global averages for 
both sexes. This excess burden can in part be attributed 
to the higher age-standardised DALY rates for cardio-
vascular diseases among females and diabetes and kidney 
diseases among males. Diabetes and kidney diseases are 
especially burdensome in southern sub-Saharan Africa, 
where the crude DALY rate (1927·2 DALYs [1693·8–2191·9] 
per 100 000 population) is more than double that 
found in other regions of sub-Saharan Africa (1233·3 
[1047·6–1432·8] in central, 887·4 [771·0–1016·7] in 
western, and 915·2 [811·3–1029·2] in eastern sub-
Saharan Africa). Ischaemic heart disease was the leading 
cause of cardiovascular disease burden among males 
(4 857 246·3 DALYs [4 417 087·3–5 429 459·4]), whereas 
cerebrovascular disease was most prominent among 
females (4 034 703·6 DALYs [3 699 338·3–4 378 417·9]). 
Age-specific DALYs for NCDs by sex in 2017 show a 
large NCD burden throughout the life course in 
males and females (figure 3). The leading causes of 
NCD burden in children under 5 years of age were those 
in the other NCDs category, including congenital 
anomalies (9856·63 DALYs [8721·99–11 841·03] per 
100 000 population) and sickle cell disorders (769·37 
DALYs per 100 000 [432·88–1076·41]), while mental 
disorders constituted a large burden among people aged 
14–39 years. The total burden of cardiovascular disease 
was similar between males and females. 
In 2017, all-age DALY rates (per 100 000 population) 
varied across sub-Saharan Africa (figure 4), ranging from 
about 12 000 DALYs (in Ethiopia) to almost 22 000 DALYs 
(in Central African Republic).
The ratio of observed to expected disease burden (based 
on SDI) of NCDs by country in 2017 is shown in figure 4. 
The countries with the lowest ratios (ie, those with a 
lower NCD burden than would be expected on the basis 
of SDI) were Ethiopia, Niger, Nigeria, Uganda, and 
Equatorial Guinea. By contrast, age-standardised DALY 
rates due to NCDs in several other countries, such as 
Lesotho, Swaziland, Congo (Brazzaville), and Central 
African Republic, exceeded what would be expected of 
countries with a similar SDI.
Discussion
This study comprehensively describes the burden of 
disease caused by NCDs in sub-Saharan Africa and 
allows a direct comparison of NCDs over time and across 
countries and populations for the first time. NCDs 
impose a formidable burden in sub-Saharan Africa and, 
Figure 4: Burden of non-communicable diseases by country in sub-Saharan Africa, 2017
(A) All-age DALY rates for non-communicable diseases (per 100 000 population). (B) Ratio of observed to expected DALYs (according to the Socio-demographic Index) for 
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although this increasing burden is largely due to a 
growing population, age-standardised DALY rates are 
also rapidly increasing in some countries, and YLDs 
are on the rise across this super-region. Furthermore, 
the burden of NCDs in all four sub-Saharan African 
regions is higher than the global average, and is now 
almost equivalent to the total burden associated with 
CMNN diseases. Thus, NCDs can no longer be neglected 
in sub-Saharan Africa and must be prioritised on health 
and development agendas. Our findings also show that a 
large amount of the NCD burden in sub-Saharan Africa 
is caused by five groups of diseases: cardiovascular 
diseases; mental disorders; neoplasms; diabetes; and 
urogenital, blood, and endocrine diseases.
There is a growing concern that cardiovascular disease 
burden, driven by increasing risk factors such as smoking 
and unhealthy diets, is likely to increase and pose 
challenges on health systems in sub-Saharan Africa.7,8,24,25 
The epidemiology of cardiovascular disease in these 
regions is unique. Historically, the burden of cardio-
vascular disease due to rheumatic disease arising from 
infectious origins has been large, while other forms of 
cardiovascular disease were thought to be relatively rare. 
Our current findings, however, indicate that strokes are 
a leading cause of cardiovascular disease burden, 
particularly among women, and this is consistent with 
the current literature.26 These high rates of stroke are 
typically explained by high rates of hypertension and a 
lack of effective treatment and control in sub-Saharan 
Africa,2 as well as low awareness among the population 
of the disease and its risk factors.27 Furthermore, a 2018 
systematic review revealed that the prevalence of 
dyslipidaemia (a leading contributor to cardiovascular 
disease) is high in Africa, affecting at least one in five 
adults in the region.28
Increasing mortality and morbidity rates from diabetes 
have also been reported previously.29 Late diagnosis and 
poor blood-glucose control exacerbate the impact of 
diabetes on the sub-Saharan African population and 
often lead to related complications.2 Chronic kidney 
disease burden (which is driven by both NCD risk factors 
and communicable diseases) is also likely to be high in 
southern sub-Saharan Africa, but efforts to understand 
the epidemiology of chronic kidney disease in Africa 
have been hampered by data quality issues.6 The 
key messages of the Lancet Diabetes & Endocrinology 
Commission on Diabetes in sub-Saharan Africa are that 
the true burden of diabetes in sub-Saharan Africa is 
unknown and that more evidence on how to effectively 
use limited resources to screen and manage diabetes is 
desperately needed.30
Given the large treatment gaps for serious mental 
health conditions, such as schizophrenia, and emerging 
substance use epidemics, mental health and substance 
use disorders are predicted to lead to 45 million YLDs by 
the year 2050 in sub-Saharan Africa.31 Calls to integrate 
evidence-based mental health services into primary 
health-care services,32 as well as early interventions in the 
life course for mental and substance use disorders, 
warrant further attention. Exploring upstream prevention 
and health promotion strategies that address some of the 
social and economic risk factors—including violence, 
poverty, forced migration and income inequality—will be 
necessary to tackle this burden effectively.33
Our findings point to a large NCD burden during 
infancy and childhood due to congenital anomalies and 
sickle cell disorders. An estimated 50–80% of children 
born with sickle cell disorder die before 5 years of age, 
and those who survive are at heightened risk of infections 
and life-threatening anaemia, but are also susceptible to 
comorbidity with stroke, kidney disease, hypertension, 
and chronic lung disease.34
NCD burden varies across sub-Saharan African 
regions and age groups. Our findings show a clear 
urgent need to prepare health services in southern sub-
Saharan Africa, which has the highest rates of diabetes, 
cardiovascular disease, and substance use disorders 
within sub-Saharan Africa.35 Countries in southern 
sub-Saharan Africa, except Namibia, have the highest 
rates of NCDs across the entire super-region, and these 
rates are rising. These countries also have higher DALYs 
than would be expected on the basis of their SDI. The 
excess NCD burden observed in southern sub-Saharan 
Africa is likely to be associated with the rate of 
urbanisation and the unhealthy lifestyles associated with 
poverty and inequality in the area.36,37
NCDs in sub-Saharan Africa must be considered in 
regard to the epidemiological contexts of each country. 
First, in many sub-Saharan African countries, as CMNN 
diseases decrease and access to treatments such 
as antiretroviral therapy increases, life expectancy in 
sub-Saharan Africa is expected to continue rising and, 
therefore, the burden of NCDs is also likely to increase.38 
Second, comorbidity is likely to be an important aspect 
of NCD epidemiology in sub-Saharan Africa.39 For 
example, antiretroviral therapy might be linked to 
increased cardiovascular risk,28,40 diabetes is associated 
with increased risk of tuberculosis and pneumonia, and 
more than a third of cancer cases in Africa are associated 
with infectious conditions.2 Some of the decline in 
cancer burden could therefore be attributed to the 
decrease in infectious disease epidemics.
The GBD 2017 study has some key limitations, which 
have been described in detail elsewhere.20,21,41 High-quality 
data for causes of death remains absent across many 
countries in sub-Saharan Africa, and caution is needed 
with use of epidemiological models and the interpretation 
of results presented here.29 Furthermore, in some 
countries in the region, the data that are available pose 
substantial challenges for cause-of-death analysis. For 
example, the analysis of all-cause mortality in countries 
without vital registration systems depends on the validity 
of sibling history data for measuring adult mortality. 
Although sibling history data have been shown to be 
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unbiased when compared with vital registration data, 
such comparisons are not available for sub-Saharan 
Africa, where sibling history data are of key importance. 
Without sufficient local evidence, another uncertainty 
arises from the reliance on evidence from high-income 
countries on the distribution of disease severity. These 
patterns could potentially reflect the effects of health care, 
or lack thereof.  Based on an assessment of the quality of 
global vital registration data, only three countries in all of 
sub-Saharan Africa achieved a score of more than one out 
of five possible stars, and vital registration and verbal 
autopsy data were not available for 17 countries in 
sub-Saharan Africa.1 Where data are available, there 
is substantial risk of over-interpreting verbal autopsy 
data, which are subject to limitations; for example, 
misclassification across broad categories of cause of death 
by verbal autopsy might be likely for causes such as 
cardiovascular diseases.
Large uncertainties surround the estimates of disease 
burden in sub-Saharan Africa, and varying data 
availability between countries can make comparisons 
difficult to interpret. Additionally, not all sources of 
uncertainty could be routinely captured in either the 
epidemiological or cause-of-death modelling processes. 
However, despite these limitations, this study provides 
the most comprehensive perspective on the burden of 
disease in sub-Saharan Africa to date.
NCDs are costly to health systems. The large burden of 
disability and the premature mortality caused by NCDs in 
the most productive ages of a person’s life means that 
individuals, families, and communities suffer.42 Many 
countries in sub-Saharan Africa need to invest in 
prevention and treatment to sustain development despite 
the costs of NCDs. There is growing evidence of the 
efficacy and cost-efficiency of integrated chronic-disease 
management models based on person-centred care. The 
rapid expansion of HIV services in sub-Saharan African 
countries provides learning experiences and potential 
models for a range of NCDs,43,44 which could be modified 
for the planning and development of effective and cost-
efficient NCD services. However, countries across sub-
Saharan Africa vary widely in terms of social and 
economic development and have had a range of historical 
trajectories, each with their own specific health challenges 
and outcomes.45 Recent advocacy efforts push for people-
centred health systems that can foster home-grown 
initiatives to address country-specific needs.46 NCDs 
continue to be severely underfunded relative to other 
health priorities in Africa.47 To ensure cost-effective 
approaches, therefore, better understanding of the 
patterns of NCD burden is essential. Efforts to support 
the strengthening of NCD surveillance and routine data 
collection must be bolstered.
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